Evidence map›Paper›PMID 36015023›Full record

ArticlePathogens (Basel, Switzerland)2022

Elevated Fasting Blood Glucose Levels Are Associated with Worse Clinical Outcomes in COVID-19 Patients Than in Pneumonia Patients with Bacterial Infections.

Wenjun Wang, Zhonglin Chai, Mark E Cooper, Paul Z Zimmet, Hua Guo, Junyu Ding, Feifei Yang, Xixiang Lin, Xu Chen, Xiao Wang and 7 more

Open access · goldAbstract read
In one paragraph

Article in Pathogens (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 2 countries.

Wenjun WangKey Laboratory of Ministry of Industry and Information Technology of Biomedical Engineering and Translational Medicine, Chinese PLA, General Hospital, Beijing 100853, China.ORCID 0000-0002-4089-0584
Zhonglin ChaiCentral Clinical School, Faculty of Medicine, Monash University, Melbourne 3004, Australia.ORCID 0000-0001-8182-8579
Mark E CooperCentral Clinical School, Faculty of Medicine, Monash University, Melbourne 3004, Australia.
Paul Z ZimmetCentral Clinical School, Faculty of Medicine, Monash University, Melbourne 3004, Australia.
Hua GuoDepartment of Pulmonary and Critical Care Medicine, Chinese PLA, General Hospital, Beijing 100853, China.
Junyu DingDepartment of Pulmonary and Critical Care Medicine, Chinese PLA, General Hospital, Beijing 100853, China.
Feifei YangKey Laboratory of Ministry of Industry and Information Technology of Biomedical Engineering and Translational Medicine, Chinese PLA, General Hospital, Beijing 100853, China.
Xixiang LinKey Laboratory of Ministry of Industry and Information Technology of Biomedical Engineering and Translational Medicine, Chinese PLA, General Hospital, Beijing 100853, China.ORCID 0000-0003-3213-1534
Xu ChenKey Laboratory of Ministry of Industry and Information Technology of Biomedical Engineering and Translational Medicine, Chinese PLA, General Hospital, Beijing 100853, China.
Xiao WangKey Laboratory of Ministry of Industry and Information Technology of Biomedical Engineering and Translational Medicine, Chinese PLA, General Hospital, Beijing 100853, China.
Qin ZhongKey Laboratory of Ministry of Industry and Information Technology of Biomedical Engineering and Translational Medicine, Chinese PLA, General Hospital, Beijing 100853, China.
Zongren LiKey Laboratory of Ministry of Industry and Information Technology of Biomedical Engineering and Translational Medicine, Chinese PLA, General Hospital, Beijing 100853, China.
Peifang ZhangBioMind Technology, Zhongguancun Medical Engineering Center, 10 Anxiang Road, 8th Floor, Beijing 100872, China.
Zhenzhou WuBioMind Technology, Zhongguancun Medical Engineering Center, 10 Anxiang Road, 8th Floor, Beijing 100872, China.
Xizhou GuanDepartment of Pulmonary and Critical Care Medicine, Chinese PLA, General Hospital, Beijing 100853, China.
Lei ZhangCentral Clinical School, Faculty of Medicine, Monash University, Melbourne 3004, Australia.ORCID 0000-0003-2343-084X
Kunlun HeKey Laboratory of Ministry of Industry and Information Technology of Biomedical Engineering and Translational Medicine, Chinese PLA, General Hospital, Beijing 100853, China.
Chinese PLA General Hospital · CNMonash University · AUZhengzhou University · CN

Funding

Ministry of Industry and Information Technology 2020-0103-3-1
6 · The paper itself

Abstract

Aims: We investigate how fasting blood glucose (FBG) levels affect the clinical severity in coronavirus disease 2019 (COVID-19) patients, pneumonia patients with sole bacterial infection, and pneumonia patients with concurrent bacterial and fungal infections. Methods: We enrolled 2761 COVID-19 patients, 1686 pneumonia patients with bacterial infections, and 2035 pneumonia patients with concurrent infections. We used multivariate logistic regression analysis to assess the associations between FBG levels and clinical severity. Results: FBG levels in COVID-19 patients were significantly higher than in other pneumonia patients during hospitalisation and at discharge (all p < 0.05). Among COVID-19 patients, the odds ratios of acute respiratory distress syndrome (ARDS), respiratory failure (RF), acute hepatitis/liver failure (AH/LF), length of stay, and intensive care unit (ICU) admission were 12.80 (95% CI, 4.80−37.96), 5.72 (2.95−11.06), 2.60 (1.20−5.32), 1.42 (1.26−1.59), and 5.16 (3.26−8.17) times higher in the FBG ≥7.0 mmol/L group than in FBG < 6.1 mmol/L group, respectively. The odds ratios of RF, AH/LF, length of stay, and ICU admission were increased to a lesser extent in pneumonia patients with sole bacterial infection (3.70 [2.21−6.29]; 1.56 [1.17−2.07]; 0.98 [0.88−1.11]; 2.06 [1.26−3.36], respectively). The odds ratios of ARDS, RF, AH/LF, length of stay, and ICU admission were increased to a lesser extent in pneumonia patients with concurrent infections (3.04 [0.36−6.41]; 2.31 [1.76−3.05]; 1.21 [0.97−1.52]; 1.02 [0.93−1.13]; 1.72 [1.19−2.50], respectively). Among COVID-19 patients, the incidence rate of ICU admission on day 21 in the FBG ≥ 7.0 mmol/L group was six times higher than in the FBG < 6.1 mmol/L group (12.30% vs. 2.21%, p < 0.001). Among other pneumonia patients, the incidence rate of ICU admission on day 21 was only two times higher. Conclusions: Elevated FBG levels at admission predict subsequent clinical severity in all pneumonia patients regardless of the underlying pathogens, but COVID-19 patients are more sensitive to FBG levels, and suffer more severe clinical complications than other pneumonia patients.

Indexed as

clinical severitiesCOVID-19fasting blood glucosepneumonia patients

Identifiers

PMID36015023
PMCPMC9416056
OpenAlexW4291017299

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.